| Literature DB >> 15123410 |
Michael G Oefelein1, Martin I Resnick.
Abstract
Prostate cancer patients are at significant risk for SREs, with up to 50% of androgen-insensitive patients experiencing an SRE at 24 months. The risk increases with the duration and type of cancer treatment. SREs decrease HRQOL, increase the cost of care, and are associated negatively with overall survival. Screening men at greatest risk (slender white men and men with hormone refractory disease or metastatic disease) with BMD measurements, and initiating empiric therapy (vitamin D3, calcium, parenteral estrogens, bisphosphates) may be warranted.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15123410 DOI： 10.1016/j.ucl.2004.02.002
Source DB: PubMed Journal: Urol Clin North Am ISSN： 0094-0143 Impact factor: 2.241